Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3201 - 3208 of 12089 results
TCPA Regulatory Update — Commission Seeks Input on Protective Order for Robocall Mitigation Database
May 17, 2021| Article| Viewpoint
TCPA Regulatory Update — Commission Considering Reduced STIR/SHAKEN Extension for Small Providers
May 17, 2021| Article| Viewpoint
What a DOJ Website Change Means for Biden’s SEP Policy
May 17, 2021| News
'Public Benefit' Corporate Model Is Making Inroads
May 17, 2021| News
Have You Been Vaccinated? Your Employer (and Everyone Else) Wants to Know
May 17, 2021| Blog| Viewpoint
Well-Being, Inclusion, & Belonging: Breaking Down Silos and Integrating DEI and Well-Being Initiatives
May 17, 2021| Webinar| Viewpoint
Robinhood Fight Will Test Mass. Securities Chief's Authority
May 14, 2021| News
CDC Vaccination Guidance Does Not Supersede State and Local Workplace Regulations
May 14, 2021| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|